Overview

Anxiety and Depression in Epilepsy: A Pilot Treatment Study

Status:
Withdrawn
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this trial aims to carry out treatment for depression and anxiety directly in the epilepsy clinic. Patients that meet eligibility criteria, including significant symptoms of depression and/or anxiety, will be enrolled in the intervention. The intervention will consist of an initial prescription for an FDA-approved medication to treat depression/anxiety and telephone-based chronic care management plan for repeated symptom measurement and side effect surveillance. The purpose of this pre-piloting limited study is to streamline recruitment, intervention and outcome assessment process in preparation for a randomized, controlled pilot of the intervention.
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Citalopram
Dexetimide